Alzheimer Drug Efficacy Gap

Alzheimer drug efficacy gap is Working memory: the surprising decline of dementia’s contrast between expensive drug development and modest treatment results. The episode says pharmaceutical companies have focused on drugs targeting protein tangles in Alzheimer patients’ brains, but results have been disappointing: only a few months of improved cognition, with high cost and serious risk.

The source specifically notes that people carrying [[APOE4DementiaRisk|APOE4]] are more likely to experience brain swelling or bleeding when taking these drugs. It also says early studies of [[GLP1Agonists|GLP-1 drugs]] have not helped people who already have dementia, while leaving open whether earlier obesity or metabolic-risk intervention could matter.

Key Claims

• Treatment gains for established dementia are described as limited in the source.
• Safety, cost, and genotype-specific risk matter when judging drug value.
• The gap strengthens the case for prevention research, not therapeutic nihilism.

Connections

• Amyloid Hypothesis Uncertainty - mechanism uncertainty behind the drug-development problem.
• APOE4 Dementia Risk - genetic risk and adverse-event branch.
• Modifiable Dementia Risk Factors, Cardiovascular-Brain Health Link, and Shingles Vaccine Dementia Signal - prevention alternatives emphasized by the episode.
• GLP-1 Agonists - adjacent metabolic-drug branch.